| Identification | Back Directory | [Name]
Acetamide, 2,2-dichloro-N-(3',4'-dimethoxy[1,1'-biphenyl]-3-yl)- | [CAS]
1616271-41-0 | [Synonyms]
CCTA-1523
Acetamide, 2,2-dichloro-N-(3',4'-dimethoxy[1,1'-biphenyl]-3-yl)- | [Molecular Formula]
C16H15Cl2NO3 | [MOL File]
1616271-41-0.mol | [Molecular Weight]
340.2 |
| Hazard Information | Back Directory | [Description]
CCTA-1523 is an inhibitor of the efflux function of ABCG2. CCTA-1523 selectively reverses ABCG2-mediated MDR in cancer cells, both in vitro and in vivo. | [Uses]
CCTA-1523 is a potent, selective, reversible and orally active ABCG2 inhibitor. CCTA-1523 shows cytotoxicity. CCTA-1523 shows anticancer activity[1]. | [in vivo]
CCTA-1523 (75 mg/kg; p.o.; q3d x 6) combined with doxorubicin (HY-15142A) (1.8 mg/kg, i.p., q3d X 6) inhibits tumor growth and increases the survival time in mice[1]. | Animal Model: | NCR nude mice (H460/MX20 xenografts)[1] | | Dosage: | 75 mg/kg (DOX ;1.8 mg/kg, i.p., q3d X 6) | | Administration: | P.o.;q3d x 6 | | Result: | Significantly inhibited the growth of H460/MX20 tumor xenografts when combined with doxorubicin compared to the vehicle control group. |
| [References]
[1] Patel A,et al. Suppression of ABCG2 mediated MDR in vitro and in vivo by a novel inhibitor of ABCG2 drug transport. Pharmacol Res. 2017 Jul;121:184-193. DOI:10.1016/j.phrs.2017.04.025 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|